Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by H.C. Wainwright analyst, Ananda Ghosh.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight Maze Therapeutics, Inc.’s potential in the precision nephrology space. The company’s proprietary COMPASS platform is a key differentiator, enabling the transformation of human genetic variant information into targeted drug programs. This positions Maze as a leader in the field, with the potential to expand its pipeline across various indications.
Maze’s development of MZE782, a first-in-class SLC6A19 small molecule inhibitor for chronic kidney disease (CKD), is particularly promising. The discovery of the D173N variant and its implications for CKD treatment, supported by UK Biobank data, suggest a significant market opportunity. Additionally, the regulatory precedents and preclinical data supporting MZE782 and MZE829 further bolster the company’s prospects. Given these factors and the current undervaluation of the stock, Ghosh sees significant upside potential, leading to the initiation of a Buy rating with a price target of $34.